Excerpt: Bringing more transparency to the program is a prime objective of legislation considered during a hearing Tuesday by the House Oversight and Government Reform subcommittee on the federal workforce, Postal Service and the District. It followed another hearing in June and a forum in September on what subcommittee Chairman Stephen F. Lynch (D-Mass.) called 'an opaque and flawed health benefit design' that results in higher drug costs than are found in other federal programs.